Nanox Release Technology S.A. is a pioneering healthcare company focused on the development of advanced drug delivery systems utilizing nanotechnology. The company specializes in creating innovative pharmaceutical products aimed at treating complex medical conditions such as cancer, hematological disorders, and infectious diseases. Their core technologies include conventional liposomes, pegylated liposomes, and PLGA (polylactide-polyglycolide copolymers) microspheres, which facilitate the targeted delivery of therapeutic agents. These systems enhance the efficacy of drugs by improving their bioavailability and reducing side effects, thereby addressing significant unmet medical needs in patient care.

The company’s pipeline features a range of nanomedicines, including nanoparticle formulations like nab-paclitaxel for various cancers and liposomal formulations such as Amphotericin B for serious fungal infections. Nanox's innovative approaches, such as pegylation and the use of nanomicelles, further optimize drug delivery by enhancing the stability and therapeutic effectiveness of the medications. Their commitment to research and development in nanobiotechnology positions Nanox as a leader in the field, with a mission to transform the treatment landscape for severe immune and inflammatory conditions through cutting-edge nanotech solutions.

Argentina

ONE STOP SOLUTION FOR DRUG DELIVERY
Nanox focuses on the development of pharmaceutical products with complex drug delivery technologies like liposomes, pegylated liposomes, and microspheres depot with PLGA (polylactide - polyglycolide copolymers) formulations.
Nanox owns worldwide rights for GM1-Nanomicelles, an innovative carrier for oncological drugs in preclinical stage currently being tested in neuro-oncology indications due its unique capacity to pass the Blood-Brain barrier

Nanox Release Technology S.A.

Company Details